CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 1.2% After Insider Buying Activity

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s share price was up 1.2% during trading on Friday following insider buying activity. The company traded as high as $44.29 and last traded at $44.16. Approximately 534,286 shares traded hands during trading, a decline of 77% from the average daily volume of 2,315,428 shares. The stock had previously closed at $43.62.

Specifically, Director John Greene acquired 7,000 shares of the firm's stock in a transaction on Wednesday, February 26th. The shares were purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now directly owns 7,000 shares in the company, valued at $313,950. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Barclays increased their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Royal Bank of Canada reduced their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. Stifel Nicolaus lowered their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a research report on Thursday, February 13th. StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a report on Thursday, February 13th. Finally, Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and boosted their target price for the company from $60.00 to $99.00 in a research report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of "Hold" and a consensus price target of $74.40.

Remove Ads

CRISPR Therapeutics Stock Down 3.7 %

The company has a market cap of $3.63 billion, a P/E ratio of -9.68 and a beta of 1.67. The company's 50-day moving average is $42.49 and its two-hundred day moving average is $45.93.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Institutional Trading of CRISPR Therapeutics

Institutional investors have recently modified their holdings of the business. Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics in the third quarter worth $40,000. Ameriflex Group Inc. purchased a new position in CRISPR Therapeutics during the 4th quarter valued at about $36,000. Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics during the 3rd quarter valued at about $43,000. Highline Wealth Partners LLC purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter worth about $39,000. Finally, Western Pacific Wealth Management LP boosted its position in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after acquiring an additional 500 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.